News | November 17, 2025
Briefs: Zydus, Divi's Laboratories and Relonchem
FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations
FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations
The investment in land is Rs. 19.85 crore
Diroximel fumarate delayed-release capsules, 231 mg, are indicated for the treatment of relapsing forms of multiple sclerosis
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Relmada expects to initiate its Phase 3 program in the first half of 2026
Caplin Point Laboratories has reported total income of Rs. 564.41 crore during the period ended September 30, 2025
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Kulzer has consolidated the production of its core product, artificial teeth, at its facility in Germany
Subscribe To Our Newsletter & Stay Updated
